Form 4: Rigel Pharmaceuticals Director Jane Wasman Acquires Shares and Stock Options as Part of Compensation

Rigel Pharmaceuticals Director Jane Wasman has acquired 2,500 shares of common stock through RSU vesting and 3,000 stock options, reflecting ongoing equity compensation and alignment with shareholder interests.

Summary

• Jane Wasman, a Director at Rigel Pharmaceuticals Inc. (RIGL), acquired 2,500 shares of common stock on May 23, 2025, at a price of $0.
• These shares were obtained upon the vesting of a Restricted Stock Unit (RSU) award, which is set to fully vest on the date prior to the company's next Annual Meeting, contingent on Ms. Wasman's continuous service on the Board of Directors.
• Following this transaction, Ms. Wasman directly beneficially owns 12,500 shares of common stock, a number that has been adjusted to reflect a one-for-ten reverse stock split effective June 27, 2024.
• Additionally, Ms. Wasman acquired 3,000 stock options with an exercise price of $18.95 on May 23, 2025, also at a price of $0.
• These stock options have an expiration date of May 23, 2035, and are structured to vest monthly over one year from the grant date, subject to her continuous service on the Board.
• After this transaction, Ms. Wasman directly beneficially owns 3,000 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: The filing indicates a director's continued receipt of equity compensation, which is a routine and generally positive sign of alignment with shareholder interests, though it doesn't reflect new strategic initiatives or financial performance.

Positives

• Director Jane Wasman's acquisition of common stock and stock options aligns her interests with shareholders, indicating continued commitment to the company's long-term success.
• The vesting of Restricted Stock Units (RSUs) and the granting of stock options are standard components of director compensation, reflecting ongoing board service and a common practice for retaining key personnel.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction, specifically the acquisition of equity by a director as part of their compensation. Such filings are routine disclosures required by the SEC for public companies and do not typically provide broader industry context or trends beyond the specific company's equity compensation practices.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director aligns their interests with those of shareholders, potentially signaling confidence in the company's long-term performance and strategic direction.
• Employees: No direct impact on employees is indicated by this filing, though it reflects standard executive and director compensation practices within the company.

Next Steps

• The Restricted Stock Units (RSUs) are expected to fully vest on the date prior to the Company's next Annual Meeting, subject to Ms. Wasman's continuous service.
• The acquired stock options will vest monthly over one year from the grant date, subject to Ms. Wasman's continuous service on the Board of Directors.

Key Dates

Recommendation

Keywords

Rigel Pharmaceuticals, RIGL, SEC Form 4, Insider Transaction, Jane Wasman, Director Compensation, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Reverse Stock Split